BEIJING, July 13 — The story begins with a number that stopped the pharmaceutical world cold: US$110 billion in cross-border deals for innovative drugs from China in just the first half of 2026. Buyers from 20 countries and regions participated, with the United States, Britain, France and Italy leading the charge, according to Chinese state media reports Monday. That figure represents roughly 80 percent of the entire 2025 total — and it landed in only six months.
For those involved in global drug development, the scale of what unfolded signals something more than a busy quarter. It marks a shift in where the world’s pharmaceutical pipeline is sourcing its most promising candidates.
Eighty-one deals closed between January and June. The buyers spanned two dozen countries, but the heavy lifting came from the traditional Western pharmaceutical powers. The US, UK, France and Italy accounted for the bulk of the activity, their companies and investors placing enormous bets on Chinese drug candidates.
At its heart, this is a story about China’s rising role in global pharmaceutical innovation. The country has spent years building its biotech sector, and the numbers now suggest the world is paying attention.
Chinese state media framed the deal flow as evidence of international confidence in the country’s drug discovery capabilities.
AI enters the equation
The report specifically highlighted China’s pivot to AI-powered drug candidates as a driver of the international interest. Artificial intelligence has become a buzzword across the industry, but the deal data suggests it is now translating into real investment decisions. Chinese companies have been investing heavily in computational drug discovery platforms, and Western buyers appear to be betting that those platforms can deliver.
The record US$110 billion figure is all the more striking given that it covers only six months of activity. If the pace holds through the second half of the year, 2026 would shatter previous records for outbound Chinese pharmaceutical deals.
Even if it slows, the first half alone has already reshaped expectations about China’s place in the global drug development ecosystem.
What the deal flow means
For Western pharmaceutical companies facing patent cliffs on blockbuster drugs, the Chinese pipeline offers a potential solution. The deals give them access to novel drug candidates at earlier stages, often at lower costs than developing those candidates in-house. For Chinese biotech firms, the partnerships provide capital and a pathway into regulated Western markets.
The 20 countries that participated in the deals represent a broad geographic spread, but the concentration in the US and Europe tells its own story. Those markets remain the largest pharmaceutical markets in the world, and their buyers are increasingly looking east for innovation.
Chinese state media characterized the deal activity as a validation of the country’s pharmaceutical sector. The report did not break down the value of individual deals or name specific companies involved, but the aggregate numbers paint a clear picture of momentum. The question now is whether the second half of 2026 can sustain the pace set in the first.
The industry will be watching closely.
